GlassScriptPhysician profile
Kara Probst
NPI 1457923849
$14,330.00
in general payments reported to CMS, 2019-2025
33 companies · $4,122 in 2025
The $4,122 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $523 · 2022: $3,439 · 2023: $3,943 · 2024: $2,304 · 2025: $4,122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,150.42 |
| Education | $217.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $2,096.49 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Abbvie INC. | $1,642.29 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $1,394.58 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $1,007.25 | 2021-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $1,004.80 | 2021-2025 | Spravato, Invega Trinza, Invega Sustenna |
| Lundbeck LLC | $930.72 | 2021-2025 | Abilify Maintena, Rexulti |
| Teva Pharmaceuticals USA, INC. | $804.16 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $704.73 | 2022-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $681.58 | 2021-2025 | Fanapt, Hetlioz |
| Corium, LLC | $645.42 | 2021-2025 | Azstarys, Adlarity |
| Axsome Therapeutics, INC. | $523.56 | 2022-2025 | Auvelity, Sunosi |
| Tris Pharma INC | $457.56 | 2022-2025 | Dyanavel Xr |
| Indivior INC. | $328.74 | 2022-2025 | Perseris, Sublocade |
| Takeda Pharmaceuticals U.S.A., INC. | $316.22 | 2022-2025 | Trintellix |
| Almatica Pharma LLC | $313.59 | 2021-2025 | Loreev Xr, Sertraline Hcl |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $230.33 | 2022-2025 | Wellbutrin, Aplenzin |
| Merck Sharp & Dohme LLC | $178.95 | 2022-2023 | Belsomra |
| Noven Therapeutics, LLC | $169.73 | 2022-2025 | Xelstrym, Secuado |
| Idorsia Pharmaceuticals US INC | $136.24 | 2022-2024 | Quviviq |
| Acadia Pharmaceuticals INC | $103.00 | 2022-2025 | Nuplazid |
| Sunovion Pharmaceuticals INC. | $102.92 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $95.12 | 2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $93.57 | 2023-2024 | Jornay Pm |
| Validus Pharmaceuticals LLC | $84.32 | 2024 | Equetro |
| Supernus Pharmaceuticals, INC. | $69.94 | 2022-2025 | Qelbree |
| Eisai INC. | $50.99 | 2021-2022 | |
| Biogen, INC. | $46.92 | 2025 | Zurzuvae |
| Collegium Pharmaceutical, INC. | $31.27 | 2025 | Jornay Pm |
| Avion Pharmaceuticals | $22.84 | 2023 | Methylphenidate Hydrochloride |
| Harmony Biosciences LLC | $18.83 | 2025 | |
| Uswm, LLC | $16.21 | 2022 | |
| Jazz Pharmaceuticals INC. | $14.82 | 2021 | |
| Neos Therapeutics, LP | $12.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kara Probst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.